“It is not that we think that Covaxin is inferior, it's just that the shot hasn't covered all the phases of trials, unlike Covishield,” he said.
Dr. Sheema, medical officer with the National Public Health Surveillance Project of the World Health Organization, said there is no need to worry. “Both vaccines, Covaxin and Covshield, are safe and secure. The difference is efficacy, meaning for how long this vaccine will protect one from that virus. Covaxin, which is in its third phase of testing, has an efficacy duration of more than one year. After the third-stage results, preference for Covaxin is likely to increase,” she said.
The Covaxin controversy has been around ever since the government gave the shot an “emergency approval” under a “clinical trial mode.” This means that the vaccine is still in Phase-3 trials, except all volunteers will get the vaccine instead of some getting the placebo. The vaccine has been embroiled in controversy, ever since it was approved based on primate data.
Business Standard had earlier reported that Bharat Biotech
would be liable to compensate volunteers under the Drugs Rules 2019, which was revealed today in the consent form asking health care workers to take part in the trial.
So far, only hospitals under the Central government are receiving Covaxin jabs in Delhi. State government hospitals have received Serum Insitute of India’s Covishield, which been given approval.
A total of 81 hospitals in Delhi are functioning as vaccination centres as of now. Delhi Chief Minister Arvind Kejriwal indicated that he plans to increase this figure gradually in accordance with vaccine availability.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.